NCT02837900已完成2 期
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Safety and Efficacy of a Second Course of Intra-articular Injections of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 14
- 主要终点
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. evaluate the safety, tolerability, and preliminary efficacy of a second course of TPX-100 who participated in study TPX-100-1
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of a second course of TPX-100 administered by intra-articular injection to subjects with osteoarthritis of the knee who participated in study TPX-100-1.
详细描述
Recruit up to 70 subjects whom participated in protocol TPX-100-1. The opposing knee that was treated will be getting 200mg in 4 weekly injections. The knee that was treated in TPX-100-1 will get randomized to either 200mg dose or a placebo lookalike. The investigators will follow these subjects for 6 months. Two MRIs of bi-lateral knees will be assessed. Also collection of ADA samples at 4 time points through the 6 month period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 25 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previous enrollment in study TPX-100-1
- •Cruciate and collateral ligament stability as defined by clinical examination
- •Able to read, understand, sign and date the subject informed consent
- •Willingness to use only acetaminophen as the primary analgesic (pain-relieving) study medication during the injection period and through study day
- •The maximum dose of acetaminophen must not exceed 2 grams/day (2000 mg per day).
- •Willingness to use only hydrocodone or hydrocodone/acetaminophen (e.g. Norco) for breakthrough pain through study day
- •Willingness not to use non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen through study day
- •Female subjects of child bearing potential who are sexually active (non-abstinent) must agree to and comply with using 2 highly effective methods of birth control (oral contraceptive, implant, injectable or indwelling intrauterine device, condom with spermicide, or sexual abstinence) while participating in the study.
排除标准
- •"Possibly, probably or definitely" drug-related SAEs in TPX-100-1; severe or ongoing "possibly, probably or definitely" related AEs in TPX-100-
- •Contraindication to MRI, including: metallic fragments, clips or devices in the brain, eye, or spinal canal; implanted devices that are magnetically programmed; weight > 300 lbs.; moderate or severe claustrophobia; previous intolerance of MRI procedure
- •Prior surgery in the knees, excluding procedures for debridement only (no previous microfracture procedure)
- •Joint replacement or any other knee surgery planned in the next 12 months
- •History of rheumatoid arthritis, psoriatic arthritis, or any other autoimmune or infectious cause for arthritis
- •Knee effusion > 2+ on the following clinical scale:
- •Zero = No wave produced on downstroke
- •Trace = Small wave on medial side with downstroke
- •1+ = Larger bulge on medial side with downstroke
- •2+ = Effusion spontaneously returns to medial side after upstroke (no downstroke necessary)
- •3+ = So much fluid that it is not possible to move the effusion out of the medial aspect of the knee screening
- •Last viscosupplementation (e.g. Synvisc® or similar hyaluronic acid product) injected into either knee < 3 months before screening
- •Last intra-articular knee injection of corticosteroids < 2 months before screening
- •Use of any steroids (except inhaled corticosteroids for respiratory problems) during the previous month before screening
- •Known hypersensitivity to TPX-100
- •Known hypersensitivity to acetaminophen or hydrocodone
- •History of arthroscopy in either knee in the last 3 months before screening
- •History of septic arthritis, gout or pseudo-gout, of either knee in previous year before screening
- •Clinical signs of acute meniscal tear (locking, new acute mechanical symptoms consistent with meniscal tear)
- •Patellar chondrocalcinosis on X-Ray
- •Skin problem, rash or hypersensitivity, affecting either knee at the injection site
- •Bleeding problem, platelet or coagulation deficiency contraindicating, in the doctor's opinion, intra-articular injection
- •Active systemic infection
- •Current treatment or treatment within the previous 2 years prior to the Screening Visit for any malignancy except basal cell or squamous cell carcinoma of the skin, unless with specific written permission is provided by the Sponsor's medical monitor
- •Women of childbearing potential who are pregnant, nursing, or planning to become pregnant, and those who do not agree to remain on an acceptable method of birth control throughout the entire study period
- •Participation in other clinical osteoarthritis drug studies, with the exception of TPX-100-1, within one year prior to screening
- •Currently taking Paclitaxel (mitotic inhibitor), natalizumab (anti-integrin monoclonal antibody), or any other anti-integrin treatment.
- •History of significant liver disease or consumption of more than 3 alcoholic drinks a day. (Definition of one alcoholic drink: 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor such as gin, rum, vodka, or whiskey).
研究组 & 干预措施
Both TX with Active
Active Comparator
Both knees with receive Active
干预措施: TPX-100 200 mg 4 times weekly for 4 weeks (Drug)
Previous LT TX knee and right placebo
Placebo Comparator
Previous left treated knee will have placebo treatment in this protocol.
干预措施: TPX-100 200 mg 4 times weekly for 4 weeks (Drug)
Previous RT TX knee and left placebo
Placebo Comparator
Previous right treated knee will have placebo treatment in this protocol.
干预措施: TPX-100 200 mg 4 times weekly for 4 weeks (Drug)
结局指标
主要结局
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. evaluate the safety, tolerability, and preliminary efficacy of a second course of TPX-100 who participated in study TPX-100-1
时间窗: Follow subjects for 6 months
Safety, Tolerability and primary efficacy
次要结局
- Change in patellar cartilage thickness in each knee as measured on standardized MRI from baseline to 6 months.(Follow subjects for 6 months)
研究者
相似试验
已完成
3 期
Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety DisorderBipolar DisorderAnxiety DisorderNCT00277654Lindner Center of HOPE111
已完成
2 期
Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative IleusIleusNCT05056935Newsoara Biopharma Co., Ltd.131
已完成
2 期
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel ResectionIleusPost-Operative AdhesionsNCT02836470Palisade Bio112
Unknown
1 期
Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult SubjectsHealthyNCT02622230Xinjiang Uygur Pharmaceutical Co., Ltd.60
已完成
1 期
Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)ADHDNCT02253745Vernalis (R&D) Ltd31